FY2025 EPS Estimates for Neurogene Increased by Analyst

Neurogene Inc. (NASDAQ:NGNE) – HC Wainwright increased their FY2025 earnings estimates for shares of Neurogene in a report released on Monday, November 17th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($4.13) per share for the year, up from their previous estimate of ($4.45). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($1.04) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.13) EPS and FY2026 earnings at ($4.34) EPS.

Several other analysts have also recently commented on NGNE. Wall Street Zen upgraded Neurogene from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $42.50.

Neurogene Trading Down 4.9%

Neurogene stock opened at $21.36 on Wednesday. The stock has a fifty day moving average price of $25.37 and a 200 day moving average price of $21.54. Neurogene has a 52 week low of $6.88 and a 52 week high of $37.27. The firm has a market capitalization of $304.85 million, a P/E ratio of -4.96 and a beta of 1.64.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.27.

Institutional Trading of Neurogene

A number of institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP boosted its position in Neurogene by 120.4% during the 1st quarter. Baker BROS. Advisors LP now owns 1,486,200 shares of the company’s stock worth $17,403,000 after purchasing an additional 811,750 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Neurogene during the third quarter worth about $12,114,000. Blair William & Co. IL boosted its position in shares of Neurogene by 141.3% in the first quarter. Blair William & Co. IL now owns 151,180 shares of the company’s stock worth $1,770,000 after buying an additional 88,540 shares during the period. Jennison Associates LLC boosted its position in shares of Neurogene by 55.0% in the second quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after buying an additional 59,479 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after buying an additional 42,880 shares in the last quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.